since they are so similar molecules, practically brothers, bio equivalent, it would be the best thing for apri and fispemiphen if cloniphene (Androxal gets FDA approval.. then apri is worth something till then nothing…and thats the irony social.
yeah when France launches , i want to know what hapned to bracco and Italy and i know pascoe has that anser and is not talking..just like "abbott is committed" and "femprox parenr first half of '14" that was outright wrong!!
after France that will be a good time to sell. look for a pump of $35 cents higher? maybe less…that would be the time ti cash out of this..imo.
unless Vitaros sales are solid. i'm betting on 60k for the 3rd quarter in V sales if less then run for the hills….
you need Androxal to make it thru the FDA… and only then does Fispemiphen have any value and with a strong patent that is the key here social..
But in this anti -testosterone w/ FDA climate now, even for non testsoterone devivatives… and after approved, every one using T products would switch immediately to androxyl thats why the FDA is being a little tough now on RPRX---want to see that recent safety data or anotehr 6 month worth…maybe.. maybe not…but till Fispemiphen is ready in- 3 years or so., to share in this lucrative men's health market.
"I can't see IsoRay (ISR) remaining independent for the remainder of 2014 due to the continued positive results from its Cesium-131 isotope. I fully expect a buyout of IsoRay of at least $10 a share by the end of this year. This company is still way undervalued and should be trading over $5 at this moment and current retail investors continue to buy at these levels and new institutions are coming on board and are establishing a position. The current daily volume of less then 1M shares is showing that longs are not selling and continue to buy more ona daily bases. If IsoRay does remain at these levels for the remainder of 2014 and that is a big IF we could see daily volume shrink to less then 100k shares."
CEO Gorsky To Travel To Richland Washington, To Lead Johnson And Johnson (JNJ) Acquisition Discussions As IsoRay (ISR) Buyout Looms Predicts Sierra World Equity Review
Latest Projections: CEO Gorsky To Travel To Richland Washington, To Lead Johnson And Johnson (JNJ) Acquisition Discussions As IsoRay (ISR) Buyout Looms Predicts Sierra World Equity Review.
Sentiment: Strong Buy
Apri is years and safety data putting this a good 2-3 years or more if ever behind Andraoxal by RPRX!!!
kep knocking it social time to wake up and smell the Androaxal approval.... just like Room tempature device Vitaros was suppoosed to be on the shelves by "mid '14" that was martin's and poscoe's quote...now.. late '16?
i just bought into RPRX at $6.33….and i am still long 1000 shares of apri down from 150k…so i want the truth to come out about al the fraud these guys pulled, imo,
Hard week boys? First your RPRX #$%$ the bed... bwahahahaha
Now APRI, goes and get's a fantastic new lead drug candidate, and a new major shareholder, followed with news that Vitaros is "exceeding the partners SALES expectations". Oh then followed by Insider buying?
Holy carp!!! You guys have had a miserable week!!! BWahahahahaha
tired of all the lies, al the phoony guidance.
FTR, i put people in to this at $2.80 because Great britain just launched Vitaros with Takeda…
and it seesm to have bombed….they have sales numbers they just don't want to give us the $60k in Vitaros sales numbers for 3rd quarter….. yet….not after more dilution occurs…
and i'd like to know why Bracco is not launching Italy yet? they only make Vitaros thru a subsidiary and know the score…it doesn't look good without Bracco launching and showing us confidence in Vitaros….
see social Pascoe made that error with Silenor.. he did the clinicals found Doxepin also works for sleep disorder..got the indication and afterwards 99% of doctors prescribed Doxepin not silenor for sleep dsorder casue the clinails were then in and the $.05 cent per pill generic was cheaper than the $7 a pill..for silenor....
do you now how pacoe discovered that doxepin made him sleepy/ how do you think? he was obviously taking dosepin for depression…..
not on fraud, so they can unload another $20M in dilution at least for a drug that already shown to be toxic to women on a long term basis…… there is no real prof tat this will work….it is a distraction on very poor Vitaros sales and the end of Femprox with no partner….and all of us not anting rayva to send $25M to sell to less then 100k people with the condition yet only 10% would need the drug that is about 10,000 people…..yeech
I wonder why they bother if they think all is lost they should sell out , Look at AT that looks pretty good. .
Sentiment: Strong Buy
I'm interested in knowing the truth i think they keep coming up with new BS to draw attention away from Viatores and Fembrox I'm going to contact the SEC and ask them to look into this company.
It's been like that for the past 3 years !!!!
They also said the low target is @2.00 hum ,where is the PPS @ now???